Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 3, Issue 4, Pages 332-336Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml300017p
Keywords
hepatitis C; HCV; MK-5172; macrocycle; genotype 3a; mutant enzymes
Categories
Ask authors/readers for more resources
A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available